Please enter your email to subscribe. By doing so, you are opting-in to receive news from Guidepost Solutions LLC.
DEA Registrants Play a Vital Role in Preventing Diversion
With roughly 64,000 people dying from drug overdoses last year and with nearly one-third of those deaths involving prescription painkillers, the current administration has declared the opioid epidemic a “National Emergency.” Every day more than 1,000 people are treated in emergency departments across the country for misusing prescription opioids. It is estimated that almost 80% of heroin users first struggled with prescription opioid addiction. In this sense, prescription painkillers are walking users to heroin’s door, across that threshold and into a deadly embrace.
To address a problem of this magnitude and complexity, a balanced, holistic approach is needed from the U.S. Interagency and the entire pharmaceutical controlled substances supply chain. These efforts must protect the public from highly addictive, potentially dangerous drugs while at the same time, ensure patients have access to their legitimate medications.
The pharmaceutical controlled substances supply chain includes approximately 1.7 million Drug Enforcement Administration (DEA) Registrants comprised of manufacturers, distributors, pharmacies, practitioners, hospitals, importers, exporters and researchers. Increased enforcement focused on DEA Registrants has brought about civil and administrative actions against Registrants not upholding their regulatory obligations. Several examples of recent enforcement actions include:
At the federal level, the Department of Justice, DEA, FBI, Office of Inspector General Health and Human Services and other members of the U.S. Interagency are developing new initiatives to complement their already robust enforcement activities. More specifically, the DEA Diversion Control Division, the primary entity responsible for regulating DEA Registrants by enforcing the CSA and implementing Code of Federal Regulations (CFR), will continue to focus its regulatory and investigative efforts on manufacturers, distributors, pharmacies, and practitioners. To support their efforts, over the next few years, the DEA plans on expanding the number of Tactical Diversion Squads; increasing the number of Diversion Investigators; hiring Special Assistant United States Attorneys dedicated to federal anti-diversion prosecutions and assigned to opioid “hotspots” around the country; hiring additional financial analysts who support investigations of DEA Registrants across the entire supply chain; and increasing the frequency of regulatory inspections.
In addition, this past summer, the Attorney General announced the formation of the Opioid Fraud and Abuse Detection Unit which will focus specifically on opioid-related healthcare fraud using data to identify and prosecute those that are contributing to the prescription opioid epidemic and hiring additional Assistant U.S. Attorneys to focus solely on investigating and prosecuting healthcare fraud related to proscription opioids.
Now, more than ever, DEA Registrants across the entire controlled substances supply chain must be proactive in their internal assessments and external engagement with government regulators. DEA registrants play a vital role in preventing diversion and maintaining a closed system of distribution. There are several concrete steps they can take now to help ensure compliance with the CSA and CFR, including but not limited to:
It should be noted that the majority of DEA Registrants are law abiding and have appropriate anti-diversion protocols in place. However, there often is a discrepancy between delineated protocols and their actual implementation. Regular, robust anti-diversion assessment and appropriate improvement and the development of policies that ensure compliance with the CSA and CFR will help avoid the financial and reputational risk that can result from enforcement actions. Proactive external engagement with government regulators and investigators is also critical to enhance communication, receive clarity regarding nuanced regulatory requirements, and minimize the litigation risk associated with government investigations.
Louis J. Milione, senior managing director at Guidepost Solutions, has more than 20 years of experience overseeing global investigations and ensuring pharmaceutical regulatory compliance. He is considered one of the U.S. government’s foremost experts in conducting proactive, highly complex investigations targeting transnational illicit networks.
Formerly the Assistant Administrator for the Drug Enforcement Administration Diversion Control Division, he was the lead regulator of pharmaceutical controlled substances and oversaw more than 1.65 million DEA Registrants across the entire pharmaceutical supply chain. Louis can be reached at email@example.com.